Lipid metabolism, atherogenesis and CD1-restricted antigen presentation

Trends in Molecular Medicine

Volumn 12, Issue 6, 2006, Pages 270-278

  Major, Amy S ^a   Joyce, Sebastian ^a   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA GALACTURONOSYLCERAMIDE; APOLIPOPROTEIN E; CD1 ANTIGEN; CD1B ANTIGEN; CD1C ANTIGEN; GAMMA INTERFERON; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; GLUCURONIC ACID; GLYCOLIPID; INTERLEUKIN 12; INTERLEUKIN 4; ISOGLOBOTRIHEXOSYLCERAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROSAPOSIN; SPHINGOLIPID ACTIVATOR PROTEIN; T6 ANTIGEN; UNCLASSIFIED DRUG;

AGELAS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ATHEROGENESIS; ATHEROSCLEROSIS; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENDOSOME; HUMAN; HYPERLIPIDEMIA; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LIPID METABOLISM; LONG TERM POTENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAMMAL; MEMBRANE TRANSPORT; NATURAL KILLER T CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SPHINGOMONAS; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARRIER PROTEINS; CYTOKINES; G(M2) ACTIVATOR PROTEIN; HUMANS; KILLER CELLS, NATURAL; LIPID METABOLISM; LIPIDS; SAPOSINS; T-LYMPHOCYTES;

EID: 33745026494     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.04.004     Document Type: Review

References (72)

1. Porcelli S., et al. Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes. Nature 341 (1989) 447-450
2. Brigl M., and Brenner M.B. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22 (2004) 817-890
3. Bezbradica J.S., and Joyce S. Natural T lymphocytes and dendritic cells: an innate duet that arouses and tempers immune responses. In: Gorczynski R.M. (Ed). Altered Immunoregulation and Human Disease (2005), Research Signpost 137-163
4. Wolf P.R., and Ploegh H.L. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu. Rev. Cell Dev. Biol. 11 (1995) 267-306
5. Joyce S., et al. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 279 (1998) 1541-1544
6. De Silva A.D., et al. Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 168 (2002) 723-733
7. Park J.J., et al. Lipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1022-1026
8. Shoulders C.C., and Shelness G.S. Current biology of MTP: implications for selective inhibition. Curr. Top. Med. Chem. 5 (2005) 283-300
9. Brozovic S., et al. CD1d function is regulated by microsomal triglyceride transfer protein. Nat. Med. 10 (2004) 535-539
10. Dougan S.K., et al. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J. Exp. Med. 202 (2005) 529-539
11. Rueckert D.G., and Schmidt K. Lipid transfer proteins. Chem. Phys. Lipids 56 (1990) 1-20
12. Sandhoff K., et al. Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell. Ann. N. Y. Acad. Sci. 845 (1998) 139-151
13. Wright C.S., et al. Structural analysis of lipid complexes of GM2-activator protein. J. Mol. Biol. 331 (2003) 951-964
14. Hiesberger T., et al. Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP). EMBO J. 17 (1998) 4617-4625
15. Zhou D., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
16. Chiu Y.H., et al. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J. Exp. Med. 189 (1999) 103-110
17. Kang S.J., and Cresswell P. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5 (2004) 175-181
18. Winau F., et al. Saposin C is required for lipid presentation by human CD1b. Nat. Immunol. 5 (2004) 169-174
19. Morimoto S., et al. Interaction of saposins, acidic lipids, and glucosylceramidase. J. Biol. Chem. 265 (1990) 1933-1937
20. Mattner J., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529
21. Kinjo Y., et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520-525
22. Sriram V., et al. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35 (2005) 1692-1701
23. van den Elzen P., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437 (2005) 906-910
24. Prigozy T.I., et al. Glycolipid antigen processing for presentation by CD1d molecules. Science 291 (2001) 664-667
25. Mahley R.W., and Rall Jr. S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1 (2000) 507-537
26. Major A.S., et al. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2351-2357
27. Nakai Y., et al. Natural killer T cells accelerate atherogenesis in mice. Blood 104 (2004) 2051-2059
28. Tupin E., et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199 (2004) 417-422
29. Schumann J., and De Libero G. Serum lipoproteins: Trojan horses of the immune response?. Trends Immunol. 27 (2006) 57-59
30. Angenieux C., et al. The cellular pathway of CD1e in immature and maturing dendritic cells. Traffic 6 (2005) 286-302
31. de la Salle H., et al. Assistance of microbial glycolipid antigen processing by CD1e. Science 310 (2005) 1321-1324
32. Hansson G.K., et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91 (2002) 281-291
33. Blake G.J., and Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ. Res. 89 (2001) 763-771
34. Salmon J.E., and Roman M.J. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr. Opin. Rheumatol. 13 (2001) 341-344
35. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42 (1999) 338-346
36. del Rincon I., and Escalante A. Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr. Rheumatol. Rep. 5 (2003) 278-286
37. Bacon P.A., et al. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun. Rev. 1 (2002) 338-347
38. Durrani O.M., et al. Primary anti-phospholipid antibody syndrome (APS): current concepts. Surv. Ophthalmol. 47 (2002) 215-238
39. Kinnunen P.K., and Holopainen J.M. Sphingomyelinase activity of LDL: a link between atherosclerosis, ceramide, and apoptosis?. Trends Cardiovasc. Med. 12 (2002) 37-42
40. Levade T., et al. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ. Res. 89 (2001) 957-968
41. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1523-1533
42. Lieu H.D., et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation 107 (2003) 1315-1321
43. Ueshima K., et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol. Pharm. Bull. 28 (2005) 247-252
44. Shah P.K. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. Rev. Cardiovasc. Med. 4 (2003) 136-141
45. Melian A., et al. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155 (1999) 775-786
46. Ostos M.A., et al. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett. 519 (2002) 23-29
47. Nassar G.M., et al. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269 (1994) 27631-27634
48. Davenport P., and Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163 (2003) 1117-1125
49. Yamamura T., et al. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr. Top. Med. Chem. 4 (2004) 561-567
50. Angeli V., et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21 (2004) 561-574
51. Castrillo A., et al. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 12 (2003) 805-816
52. Joseph S.B., et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119 (2004) 299-309
53. -/- mice. Am. J. Pathol. 157 (2000) 1819-1824
54. -/- mice. J. Interferon Cytokine Res. 22 (2002) 661-670
55. -/- mice through release of interferon-γ. Circ. Res. 90 (2002) E34-E38
56. Huber S.A., et al. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 103 (2001) 2610-2616
57. George J., et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104 (2001) 1646-1650
58. Cyrus T., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103 (1999) 1597-1604
59. + T cells upon NK T or T cell activation. J. Immunol. 165 (2000) 4305-4311
60. Eberl G., and MacDonald H.R. Rapid death and regeneration of NKT cells in anti-CD3ε{lunate}- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9 (1998) 345-353
61. Brigl M., et al. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4 (2003) 1230-1237
62. Wu D.Y., et al. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198 (2003) 173-181
63. Kolter T., et al. Lipid-binding proteins in membrane digestion, antigen presentation, and antimicrobial defense. J. Biol. Chem. 280 (2005) 41125-41128
64. Zhou D., et al. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303 (2004) 523-527
65. Ichikawa S., and Hirabayashi Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol. 8 (1998) 198-202
66. Kobayashi T., et al. Lipid domains in the endocytic pathway. Semin. Cell Dev. Biol. 12 (2001) 173-182
67. Nickel W., et al. Protein and lipid sorting between the endoplasmic reticulum and the Golgi complex. Semin. Cell Dev. Biol. 9 (1998) 493-501
68. Taniguchi M., et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21 (2003) 483-513
69. Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol. Res. 30 (2004) 139-153
70. Van Kaer L., and Joyce S. Innate immunity: NKT cells in the spotlight. Curr. Biol. 15 (2005) R429-R431
71. Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5 (2005) 31-42
72. Parekh V.V., et al. iNKT-cell responses to glycolipids. Crit. Rev. Immunol. 25 (2005) 183-213